|
GSK PLC on Sunday reported positive data for its cancer therapy candidate mocertatug rezetecan. The London-based pharmaceutical firm is assessing mocertatug rezetecan as a treatment for platinum-resistant ovarian cancer and endometrial cancer. Mocertatug rezetecan is an antibody-drug conjugate which targets the B7-H4 antigen. GSK acquired worldwide commercialisation rights, excluding mainland China, Hong Kong, Macau and Taiwan, from Hansoh Pharmaceutical Group Co Ltd. Patients given the drug as a monotherapy at the highest doses tested registered an objective response rate of 62% in PROC and 67% in recurrent or advanced endometrial cancer. GSK said the outcome ‘reinforces [mocertatug rezetecan’s] broad potential in gynaecologic cancers and further validates the relevance of targeting B7-H4’. At the interim analysis mark, the median duration of response had not yet been reached, GSK noted. The recommended dose for the first phase-three trial is 5.8 milligrams per kilogram. Hesham Abdullah, the company’s senior vice president and global head of Oncology Research & Development added: ‘Treatment of gynaecological cancers remains a major challenge, with a pressing need for new therapies that offer improved response rates. With Mo-Rez, we now have compelling evidence of a promising clinical profile, with response rates that support accelerating development into five pivotal global phase III trials later this year across ovarian and endometrial cancers, including earlier line settings.’ GSK shares close 0.5% higher at 2,177.00 pence on Friday in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
